Moderna files for full US approval of COVID-19 vaccine

FILE PHOTO: A healthcare worker holds a vial of the Moderna COVID-19 Vaccine at a pop-up vaccination site operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in Manhattan in New York City, New York, U.S., Jan. 29, 2021. REUTERS/Mike Segar

(Mike Segar, Reuters)

1 photo

Estimated read time: 2-3 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (Reuters) — Moderna on Tuesday filed for full U.S. approval of its COVID-19 vaccine, which is currently only authorized for emergency use in the country, becoming the second drugmaker to seek a broader regulatory nod.

The development comes weeks after rival Pfizer and its German partner BioNTech SE sought full approval for their COVID-19 vaccine in the United States.

Full approval for the vaccines, which are at the forefront of global immunization efforts, could be an important step in allaying vaccine hesitancy, a growing concern in the United States and other wealthy nations.

It would also allow the vaccine makers to market their shots directly, as well as help companies and government agencies looking for vaccinations for their employees.

Moderna said it will continue to submit data to the U.S. Food and Drug Administration on a rolling basis over the coming weeks with a request for a priority review.

On completion of the submission, the FDA will notify the company when it is formally accepted for review, it added.

Moderna has an agreement with the U.S. government to supply 300 million doses of its COVID-19 vaccine.

More than 151 million doses of Moderna's vaccine have been distributed around the United States, with roughly 124.5 million shots administered as of Monday, according to the U.S. Centers for Disease Control and Prevention.

Under an emergency use authorization, the FDA makes a product available to the public during an emergency based on the best available evidence, without waiting for all the evidence needed for full approval or clearance.

Moderna said in April its vaccine showed strong protection against the coronavirus six months after people received their second shot, with efficacy of more than 90% against all cases of COVID-19 and more than 95 percent against severe COVID-19.

(Reporting by Amruta Khandekar in Bengaluru; Editing by Shounak Dasgupta and Shailesh Kuber)

© Copyright Thomson Reuters 2021


Related stories

Most recent Business & Tech stories

Related topics

Business & TechCoronavirus


    Catch up on the top news and features from, sent weekly.
    By subscribing, you acknowledge and agree to's Terms of Use and Privacy Policy.

    KSL Weather Forecast